Extended Data Fig. 2. Treatment of mice bearing OVA-negative EL-4 tumors with the pEr-OVA-CpG B nanovaccine.
(a) Immunization schedule, EL-4 tumor bearing C57BL/6 mice were immunized by subcutaneous injection at the mouse tail-base with the pErNP-OVA-CpG B nanovaccine on day 0, 7 and 14. Also shown are NIR-IIb luminescence images (975 nm excitation with a power density of ~50 mW cm−2, 1500–1700 nm detection, exposure times 20 ms, CW mode) showing the vaccine trafficking pathways after subcutaneous injection at the tail-base of a mouse. Images were recorded at different time points as indicated post injection. (b) Photographs of C57BL/6 mice treated with pErNP-OVA-CpG B vaccines at different time points. (c) Tumor volume measured at different time points post s.c. injection of pErNP-OVA-CPG B (n = 5). The EL-4 tumors showed no response to the pErNP-OVA-CpG B nanovaccine and grew unabated.